The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials

World Psychiatry

Volumn 18, Issue 1, 2019, Pages 53-66

  Vancampfort, Davy ^a,b   Firth, Joseph ^c,d,e   Correll, Christoph U ^f,g,h   Solmi, Marco ⁱ   Siskind, Dan ^j,k   De Hert, Marc ^b,l   Carney, Rebekah ^d   Koyanagi, Ai ^m,n   Carvalho, André F ^o,p   Gaughran, Fiona ^q,r   Stubbs, Brendon ^q,r  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c WESTERN SYDNEY UNIVERSITY   (Australia)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^g ZUCKER HILLSIDE HOSPITAL   (United States)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j Metro South Addiction and Mental Health Service   (Australia)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^m UNIVERSITY OF BARCELONA   (Spain)

ⁿ CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^o CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^p UNIVERSITY OF TORONTO   (Canada)

^q SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^r KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

antipsychotic switching; blood pressure; body weight; cholesterol; dietary interventions; exercise interventions; glucose; insulin; lifestyle counseling; metformin; physical health; psychosis; Schizophrenia; topiramate; tryglicerides

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; CHOLESTEROL; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS SIBUTRAMINE; NIZATIDINE; OLANZAPINE; PLACEBO; QUETIAPINE; TOPIRAMATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT LOSS; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DEPRESSION; DIARRHEA; DIET THERAPY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; GLUCOSE BLOOD LEVEL; HEALTH; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HUMAN; INSOMNIA; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MENTAL DISEASE; META ANALYSIS; NAUSEA; NAUSEA AND VOMITING; PARESTHESIA; PREMATURE MORTALITY; PRIORITY JOURNAL; PSYCHOEDUCATION; RESTLESSNESS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; XEROSTOMIA;

EID: 85059358788     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20614     Document Type: Article

References (66)

1. Vancampfort D, Wampers M, Mitchell A et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013;12:240-50
2. Stubbs B, De Hert M, Sepehry A et al. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand 2014;130:470-86
3. Stubbs B, Koyanagi A, Veronese N et al. Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. BMC Med 2016;14:189
4. Vancampfort D, Stubbs B, Mitchell AJ et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015;14:339-47
5. Liu NH, Daumit GL, Dua T et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry 2017;16:30-40
6. Vancampfort D, Firth J, Schuch FB et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 2017;16:308-15
7. Firth J, Stubbs B, Teasdale SB et al. Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. World Psychiatry 2018;17:365-6
8. Schroeder SA. Smoking cessation should be an integral part of serious mental illness treatment. World Psychiatry 2016;15:175-6
9. Correll C, Detraux J, De Lepeleire J et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14:119-36
10. Galling B, Roldán A, Nielsen RE et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 2016;73:247-59
11. Vancampfort D, Correll CU, Galling B et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016;15:166-74
12. De Hert M, Schreurs V, Vancampfort D et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009;8:15-22
13. Correll CU, Solmi M, Veronese N et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017;16:163-80
14. Schoepf D, Uppal H, Potluri R et al. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Clin Neurosci 2014;264:3-28
15. Stubbs B, Koyanagi A, Thompson T et al. The epidemiology of back pain and its relationship with depression, psychosis, anxiety, sleep disturbances, and stress sensitivity: data from 43 low- and middle-income countries. Gen Hosp Psychiatry 2016;43:63-70
16. Stubbs B, Gaughran F, Mitchell AJ et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry 2015;37:126-33
17. Vancampfort D, Rosenbaum S, Probst M et al. Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta-analysis. Acta Psychiatr Scand 2015;132:131-43
18. Vancampfort D, Rosenbaum S, Schuch F et al. Cardiorespiratory fitness in severe mental illness: a systematic review and meta-analysis. Sports Med 2017;47:343-52
19. Vancampfort D, Guelinckx H, Probst M et al. Health-related quality of life and aerobic fitness in people with schizophrenia. Int J Ment Health Nurs 2015;24:394-402
20. Vancampfort D, Probst M, Scheewe T et al. Lack of physical activity during leisure time contributes to an impaired health related quality of life in patients with schizophrenia. Schizophr Res 2011;129:122-7
21. Saxena S, Maj M. Physical health of people with severe mental disorders: leave no one behind. World Psychiatry 2017;16:1-2
22. Mitchell AJ, Delaffon V, Vancampfort D et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012;42:125-47
23. Zhuo C, Tao R, Jiang R et al. Cancer mortality in patients with schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2017;211:7-13
24. Hjorthøj C, Stürup AE, McGrath JJ et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017;4:295-301
25. Oakley P, Kisely S, Baxter A et al. Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis. J Psychiatr Res 2018;102:245-53
26. Moore S, Shiers D, Daly B et al. Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. Acta Psychiatr Scand 2015;132:109-21
27. De Hert M, Cohen D, Bobes J et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10:138-51
28. Lambert TJ, Reavley NJ, Jorm AF et al. Royal Australian and New Zealand College of Psychiatrists expert consensus statement for the treatment, management and monitoring of the physical health of people with an enduring psychotic illness. Aust N Z J Psychiatry 2017;51:322-37
29. Cooper SJ, Reynolds GP, Barnes T et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016;30:717-48
30. Bobes-García J, Saiz-Ruiz J, Bernardo-Arroyo M et al. Delphi consensus on the physical health of patients with schizophrenia: evaluation of the recommendations of the Spanish Societies of Psychiatry and Biological Psychiatry by a panel of experts. Actas Esp Psiquiatr 2012;40:114-28
31. Chaudhry I, Jordan J, Cousin F-R et al. Management of physical health in patients with schizophrenia: international insights. Eur Psychiatry 2010;25:S37-40
32. Saravane D, Feve B, Frances Y et al. Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale 2009;35:330-9
33. De Hert M, Dekker JM, Wood D et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24
34. Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49
35. Cohen J. Statistical power analysis for the behavioral sciences. New York: Lawrence Erlbaum, 1988
36. Shea BJ, Hamel C, Wells GA et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62:1013-20
37. Correll CU, Rubio JM, Inczedy-Farkas G et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017;74:675-84
38. Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
39. Goh KK, Chen C-H, Lu M-L. Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials. Int J Psychiatry Clin Pract 2018:1-19
40. Siskind D, Hahn M, Correll CU et al. Glucagon-like peptide-1 receptor-agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab (in press)
41. Zheng W, Zhang Q-E, Cai D-B et al. Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials. Pharmacopsychiatry (in press)
42. Gu X-J, Chen R, Sun C-H et al. Effect of adjunctive ranitidine for antipsychotic-induced weight gain: a systematic review of randomized placebo-controlled trials. J Int Med Res 2018;46:22-32
43. Galling B, Roldán A, Hagi K et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017;16:77-89
44. Teasdale SB, Ward PB, Rosenbaum S et al. Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry 2017;210:110-8
45. Zheng W, Wang S, Ungvari GS et al. Amantadine for antipsychotic-related weight gain: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 2017;37:341-6
46. Siskind DJ, Leung J, Russell AW et al. Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLoS One 2016;11:e0156208
47. Zheng W, Zheng Y-J, Li X-B et al. Efficacy and safety of adjunctive aripiprazole in schizophrenia: meta-analysis of randomized controlled trials. J Clin Psychopharmacol 2016;36:628-36
48. Zimbron J, Khandaker GM, Toschi C et al. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome. Eur Neuropsychopharmacol 2016;26:1353-65
49. Zheng W, Li X-B, Tang Y-L et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 2015;35:499-509
50. Firth J, Cotter J, Elliott R et al. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med 2015;45:1343-61
51. Bruins J, Jörg F, Bruggeman R et al. The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. PLoS One 2014;9:e112276
52. Kishi T, Iwata N. Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: a meta-analysis of randomized placebo-controlled trials. Pharmacopsychiatry 2015;48:30-6
53. Srisurapanont M, Suttajit S, Maneeton N et al. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res 2015;62:38-47
54. Gierisch JM, Nieuwsma JA, Bradford DW et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry 2014;75:e424-40
55. Mizuno Y, Suzuki T, Nakagawa A et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014;40:1385-403
56. Pearsall R, Smith DJ, Pelosi A et al. Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis. BMC Psychiatry 2014;14:117
57. Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res 2013;47:1143-9
58. Bonfioli E, Berti L, Goss C et al. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 2012;12:78
59. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140:159-68
60. Praharaj SK, Sharma PSVN. Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol 2012;2:151-6
61. Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol 2011;25:299-305
62. Praharaj SK, Jana AK, Goyal N et al. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol 2011;71:377-82
63. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C et al. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008;193:101-7
64. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520-30
65. Mukundan A, Faulkner G, Cohn T et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010;12:CD006629
66. Yalom ID. Inpatient group psychotherapy. New York: Basic Books, 1983